Cleveland biotechnology company Athersys Inc received Fast Track designation from the U.S. Food and Drug Administration in acute respiratory distress syndrome, or ARDS.
In January 2019,the company ran a randomized, double-blind placebo-controlled exploratory Phase 2 clinical study evaluating MultiStem administration to patients with ARDS.
In the study, patients who received MultiStem treatment within several days after being diagnosed with ARDS and being placed on a ventilator experienced lower mortality, increased ventilator-free days, and increased ICU-free days during the initial 28-day clinical assessment period relative to patients receiving placebo.
Garrett Van Wagoner
Athersys Enters Into New $100 Million Equity Facility with Aspire Capital
Athersys Inc. extends agreement with Healios for a license to MultiStem therapy for indications in China
Athersys: A Lucrative China Stem Cell Licensing Deal Seems Imminent
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: Stem cell technologyTechnology used for isolating, generating, growing and controlling the differentiation of stem cells into specialized cells and the application of stem cell technology for medical and non-medical purposes such as producing meat through cellular agriculture.
- Stem cellStem cells are self-renewing cells that have the potential to become multiple different cell types in the body. Stem cells are found in developing embryos. Adult stem cells maintain and repair tissues throughout life. Induced pluripotent stem cells are a type of stem cell derived from adult cells that are reprogrammed in the lab.